Indian Journal of Pathology and Microbiology (Jan 2018)

BRAFV600E mutation in hairy cell leukemia: A single-center experience

  • Asma Bibi,
  • Shrutika Java,
  • Shruti Chaudhary,
  • Swapnali Joshi,
  • Russel Mascerhenas,
  • Nikhil Rabade,
  • Prashant Tembhare,
  • Papagudi Ganesan Subramanian,
  • Sumeet Gujral,
  • Hari Menon,
  • Navin Khattry,
  • Manju Sengar,
  • Bhausaheb Bagal,
  • Hasmukh Jain,
  • Nikhil Patkar

DOI
https://doi.org/10.4103/IJPM.IJPM_484_16
Journal volume & issue
Vol. 61, no. 4
pp. 532 – 536

Abstract

Read online

Background: BRAFV600E mutation has been reported as a unique genetic lesion of hairy cell leukemia (HCL), a subset of which lacks this lesion and shows adverse outcomes. Aims: To determine the prevalence of BRAFV600E in HCL from our center and derive clinicopathological correlation, if any. Materials and Methods: A 9-year retrospective analysis of 46 consecutive cases of HCL diagnosed on morphology and immunophenotyping was done. Stained smears were used as samples for amplification refractory mutation system polymerase-chain reaction using fluorescent primers for mutation detection. Results: BRAFV600E mutation was detected in 41/46 patients (89.1%) while absent in control samples of chronic lymphocytic leukemia. Cases mimicking HCL-variant clinically or immunophenotypically too showed the presence of this mutation. HCL with mutated BRAF presented at a younger age. No statistical difference in blood counts, tumor load, and immunophenotype patterns existed among BRAF mutated and unmutated group. Nine patients (45%) with mutated BRAF had residual disease following treatment with cladribine. Conclusion: BRAFV600E mutation analysis has a definitive role in the diagnosis of HCL.

Keywords